Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
KDMF
0
NDC API
0
VMF
0
FDF
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Finished Drug Prices
NA
1. 3-carboxymethyl-5-(methyl-3-phenylpropenylidene)rhodanine
2. Ono 2
3. Ono 2235
4. Ono-2
5. Ono-2235
1. 82159-09-9
2. Kinedak
3. Epalrestatum
4. Epalrestat [inn]
5. Ono 2235
6. Ono-2235
7. Ono-2
8. 2-((z)-5-((e)-2-methyl-3-phenylallylidene)-4-oxo-2-thioxothiazolidin-3-yl)acetic Acid
9. Aldonil
10. Aldorin
11. Tanglin
12. 2-[(5z)-5-[(e)-2-methyl-3-phenylprop-2-enylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]acetic Acid
13. Chembl56337
14. 5-((1z,2e)-2-methyl-3-phenylpropenylidene)-4-oxo-2-thioxo-3-thiazolidineacetic Acid
15. Chebi:31539
16. Ono2235
17. 5-((z,e)-beta-methylcinnamylidene)-4-oxo-2-thioxo-3-thiazolidineacetic Acid
18. Mfcd00865484
19. 424dv0807x
20. {(5z)-5-[(2e)-2-methyl-3-phenylprop-2-en-1-ylidene]-4-oxo-2-thioxo-1,3-thiazolidin-3-yl}acetic Acid
21. Epalrestatum [latin]
22. {5-[(e)-2-methyl-3-phenyl-prop-2-en-(z)-ylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-acetic Acid
23. 2-[(5z)-5-[(2e)-2-methyl-3-phenylprop-2-en-1-ylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]acetic Acid
24. Ono 2
25. Kinedak (tn)
26. Unii-424dv0807x
27. Ncgc00164613-01
28. Epalrestat- Bio-x
29. 5-[(1z, 2e)-2-methyl-3-phenylpropenylidene]-4-oxo2-thioxo-3-thiazolidineacetic Acid
30. Epalrestat [mi]
31. Epalrestat [jan]
32. Epalrestat (jp17/inn)
33. Epalrestat [mart.]
34. 3-thiazolidineacetic Acid, 5-(2-methyl-3-phenyl-2-propenylidene)-4-oxo-2-thioxo-, (e,e)-
35. Epalrestat [who-dd]
36. Schembl49049
37. Mls000806985
38. Dtxsid1046479
39. Gtpl11371
40. Regid_for_cid_1549120
41. Hms2747m09
42. Hms3887a17
43. Zinc1533688
44. Bbl029067
45. Bdbm50049730
46. S2035
47. Stk337187
48. Akos000274207
49. Bcp9000649
50. Ccg-267693
51. Db15293
52. Ncgc00164613-08
53. Ncgc00164613-12
54. As-13345
55. Be164412
56. Hy-66009
57. Smr000414799
58. Bcp0726000053
59. E0906
60. Sw219826-1
61. D01688
62. Ab00647195_06
63. 159e099
64. Q5382029
65. [5-(2-methyl-3-phenyl-allylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-acetic Acid
66. 2-(5-(2-methyl-3-phenylallylidene)-4-oxo-2-thioxothiazolidin-3-yl)acetic Acid
67. 5-((z,e)-.beta.-methylcinnamylidene)-4-oxo-2-thioxo-3-thiazolidineacetic Acid
68. (5-[(e)-2-methyl-3-phenyl-prop-2-en-(z)-ylidene]-4-oxo-2-thioxo-thiazolidin-3-yl)-acetic Acid 82159-
69. {(5z)-5-[(2e)-2-methyl-3-phenylprop-2-enylidene]-4-oxo-2-thioxo-1,3-thiazolidin-3-yl}acetic Acid
70. 2-[(5z)-5-[(e)-3-phenil-2-methylprop-2-enylidene]-4-oxo-2-thioxo-3-thiazolidinyl]acetic Acid
Molecular Weight | 319.4 g/mol |
---|---|
Molecular Formula | C15H13NO3S2 |
XLogP3 | 3.8 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 5 |
Rotatable Bond Count | 4 |
Exact Mass | 319.03368562 g/mol |
Monoisotopic Mass | 319.03368562 g/mol |
Topological Polar Surface Area | 115 Ų |
Heavy Atom Count | 21 |
Formal Charge | 0 |
Complexity | 519 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 2 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Enzyme Inhibitors
Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Epalrestat manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Epalrestat, including repackagers and relabelers. The FDA regulates Epalrestat manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Epalrestat API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Epalrestat manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Epalrestat supplier is an individual or a company that provides Epalrestat active pharmaceutical ingredient (API) or Epalrestat finished formulations upon request. The Epalrestat suppliers may include Epalrestat API manufacturers, exporters, distributors and traders.
click here to find a list of Epalrestat suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Epalrestat Drug Master File in Japan (Epalrestat JDMF) empowers Epalrestat API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Epalrestat JDMF during the approval evaluation for pharmaceutical products. At the time of Epalrestat JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Epalrestat suppliers with JDMF on PharmaCompass.
A Epalrestat written confirmation (Epalrestat WC) is an official document issued by a regulatory agency to a Epalrestat manufacturer, verifying that the manufacturing facility of a Epalrestat active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Epalrestat APIs or Epalrestat finished pharmaceutical products to another nation, regulatory agencies frequently require a Epalrestat WC (written confirmation) as part of the regulatory process.
click here to find a list of Epalrestat suppliers with Written Confirmation (WC) on PharmaCompass.
Epalrestat Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Epalrestat GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Epalrestat GMP manufacturer or Epalrestat GMP API supplier for your needs.
A Epalrestat CoA (Certificate of Analysis) is a formal document that attests to Epalrestat's compliance with Epalrestat specifications and serves as a tool for batch-level quality control.
Epalrestat CoA mostly includes findings from lab analyses of a specific batch. For each Epalrestat CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Epalrestat may be tested according to a variety of international standards, such as European Pharmacopoeia (Epalrestat EP), Epalrestat JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Epalrestat USP).
LOOKING FOR A SUPPLIER?